Rinsho Shinkeigaku (Clinical Neurology)


Cell therapy for Parkinson's disease with induced pluripotent stem cells

Asuka Morizane, M.D., Ph.D.1)

1)Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University

Cell therapy for Parkinson's disease has a history of being applied clinically with aborted embryos as donor source. Efficacy of the therapy under the appropriate condition has been reported. Based on this experience and the advancement of stem cell technology, clinical trials of cell therapy with embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs) are going to start soon in several countries. In Japan a physician-initiated clinical trial of iPSC-based therapy for Parkinson's disease has launched since 2018. This trial adopts allogeneic transplantation with a cell line from iPSC stock. This article discusses patient selection, procedure, and risk of the therapy. It also introduces the world's current situation of the cell therapy for Parkinson's disease.
Full Text of this Article in Japanese PDF (766K)

(CLINICA NEUROL, 59: 119|124, 2019)
key words: induced pluripotent stem cell, Parkinson, cell therapy, clinical trial

(Received: 29-Sep-18)